Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
CVS to close ‘select’ pharmacies in Target stores starting in February
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Bertha Coombs joins ‘Closing Bell’ to report on the announcement from CVS on their plan to close select pharmacies inside Target locations beginning in February.
Watch CNBC’s full interview with Wells Fargo’s Ike Boruchow
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Ike Boruchow, Wells Fargo Securities senior equity analyst, joins ‘Power Lunch’ to discuss why he now believes there’s a rebound in the retail sector, what he would be buying right now and more. 04:02 Thu, Oct 20 20223:00 PM EDT
Watch the full discussion on Disney with RBC’s Kutgun Maral and Cowen’s Doug Cruetz
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Kutgun Maral of RBC Capital Markets and Doug Creutz of Cowen join ‘The Exchange’ to discuss streaming stocks like Netflix, Paramount Global and Disney. 07:44 Mon, Jul 18 20221:58 PM EDT
Small businesses are continuing to worry about wage growth, says U.S. Chamber of Commerce CEO
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Squawk on the Street Suzanne Clark, U.S. Chamber of Commerce CEO, joins ‘Squawk on the Street’ to discuss the state of American business. 05:07 2 hours ago
2020 will see more store closures, expert says
Stacey Widlitz, president at SW Retail Advisors, speaks to CNBC about the retail picture in both the U.K. and the U.S.
Wells Fargo’s Mike Mayo says there’s a chance for Citi shares to head higher
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mike Mayo, Wells Fargo analyst, joins ‘Closing Bell: Overtime’ to discuss why he raised his price target on Citigroup to $70 dollars. 04:27 Tue, May 17 20224:43 PM EDT
